1.   

On 17 September 2021, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1).

This notification concerns the following undertakings:

—	CVC Capital Partners SICAV-FIS S.A. (‘CVC’, Luxembourg),

—	Cooper Consumer Health S.A.S. and its subsidiaries (‘Cooper’, France).

CVC acquires within the meaning of Article 3(1)(b) of the Merger Regulation sole control of the whole of Cooper.

The concentration is accomplished by way of purchase of securities.

2.   

The business activities of the undertakings concerned are:

—	CVC manages investment funds and platforms,

—	Cooper produces and markets various self-care products used for diagnosis, prevention, treatment and enhancements.

3.   

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

4.   

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

Case M.10247 CVC/ Cooper

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

Email: COMP-MERGER-REGISTRY@ec.europa.eu

Fax +32 22964301

Postal address:

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË